Karim Fizazi Selected Research

abiraterone

1/2022	Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
1/2022	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.
1/2022	Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
1/2022	Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
1/2022	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
12/2021	Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
10/2021	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
8/2021	Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
1/2021	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
12/2020	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karim Fizazi Research Topics

Disease

221	Prostatic Neoplasms (Prostate Cancer) 10/2022 - 03/2002
74	Neoplasms (Cancer) 07/2022 - 02/2002
59	Neoplasm Metastasis (Metastasis) 02/2022 - 03/2002
37	Pain (Aches) 07/2022 - 03/2003
25	Disease Progression 01/2022 - 06/2014
16	Fatigue 03/2022 - 01/2012
13	Seminoma 01/2022 - 08/2003
13	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 10/2021 - 10/2004
12	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 07/2003
9	Hypertension (High Blood Pressure) 01/2022 - 05/2011
7	Circulating Neoplastic Cells 01/2020 - 01/2016
6	Febrile Neutropenia 01/2022 - 02/2013
6	Asthenia 01/2022 - 04/2015
6	Neutropenia 01/2022 - 02/2013
6	Bone Resorption 01/2013 - 07/2003
6	Carcinoma (Carcinomatosis) 07/2009 - 10/2002
5	Breast Neoplasms (Breast Cancer) 06/2022 - 04/2009
5	Edema (Dropsy) 03/2022 - 11/2012
5	Nausea 01/2022 - 05/2013
4	Pneumonia (Pneumonitis) 01/2022 - 04/2015
4	Diarrhea 10/2021 - 09/2012
4	Testicular Neoplasms (Testicular Cancer) 01/2021 - 08/2011
4	Kidney Neoplasms (Kidney Cancer) 01/2020 - 04/2014
3	Cancer Pain 01/2022 - 01/2013
3	Adenocarcinoma 01/2021 - 12/2007
3	Hypocalcemia 02/2019 - 02/2014
3	Osteonecrosis (Kienbock's Disease) 02/2019 - 01/2012
3	Seizures (Absence Seizure) 01/2019 - 09/2012
3	Hypokalemia 01/2018 - 05/2011
3	Urinary Bladder Neoplasms (Bladder Cancer) 10/2016 - 07/2006

Drug/Important Bio-Agent (IBA)

61	Docetaxel (Taxotere)FDA Link 03/2022 - 09/2004
56	AndrogensIBA 02/2022 - 03/2002
38	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 07/2003
36	enzalutamideIBA 03/2022 - 09/2012
36	Prednisone (Sone)FDA LinkGeneric 02/2022 - 05/2011
34	Abiraterone AcetateIBA 02/2022 - 05/2011
28	abirateroneIBA 01/2022 - 05/2011
27	Hormones (Hormone)IBA 10/2022 - 10/2008
24	Androgen Receptors (Androgen Receptor)IBA 02/2022 - 03/2002
17	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 02/2002
16	cabazitaxel FDA Link 03/2022 - 06/2014
16	Denosumab FDA Link 02/2019 - 04/2009
14	darolutamideIBA 07/2022 - 08/2014
13	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2010
11	Pharmaceutical PreparationsIBA 01/2022 - 07/2003
10	taxaneIBA 06/2022 - 01/2010
10	Poly(ADP-ribose) Polymerase InhibitorsIBA 05/2022 - 01/2020
10	Diphosphonates (Bisphosphonates)IBA 02/2016 - 04/2009
8	Estramustine FDA Link 12/2020 - 09/2004
8	Zoledronic Acid (Zometa)FDA Link 02/2019 - 03/2011
7	AntigensIBA 10/2022 - 05/2015
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2002
7	IpilimumabIBA 01/2021 - 06/2014
7	collagen type I trimeric cross-linked peptideIBA 09/2015 - 04/2009
7	Monoclonal AntibodiesIBA 07/2015 - 04/2009
6	Etoposide (VP 16)FDA LinkGeneric 01/2022 - 10/2002
6	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 12/2006
6	Immune Checkpoint InhibitorsIBA 01/2022 - 10/2017
6	Alkaline PhosphataseIBA 01/2020 - 01/2013
5	Taxoids (Taxanes)IBA 03/2022 - 06/2013
5	olaparibIBA 01/2022 - 01/2020
5	TabletsIBA 01/2022 - 01/2016
5	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2021 - 12/2002
5	Biological ProductsIBA 06/2021 - 12/2002
5	Testosterone (Sustanon)FDA Link 12/2020 - 08/2014
5	RadiopharmaceuticalsIBA 01/2020 - 05/2009
5	Androgen Receptor AntagonistsIBA 10/2019 - 12/2017
4	PlacebosIBA 02/2022 - 01/2018
4	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2020 - 01/2013
4	Hemoglobins (Hemoglobin)IBA 01/2020 - 07/2015
4	Radium-223IBA 01/2019 - 11/2015
4	Gemcitabine FDA Link 01/2019 - 09/2003
4	CreatinineIBA 09/2015 - 04/2009
4	Endothelins (Endothelin)IBA 05/2013 - 07/2003
3	talazoparibIBA 06/2022 - 01/2021
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 05/2022 - 01/2020
3	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2022 - 01/2016
3	antiarrhythmic peptide (AAP)IBA 02/2022 - 11/2018
3	NivolumabIBA 01/2022 - 10/2016
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2018
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 10/2019
3	Opiate AlkaloidsIBA 01/2022 - 01/2013
3	rucaparibIBA 12/2021 - 01/2020
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2020 - 02/2013
3	cabozantinibIBA 01/2020 - 01/2016
3	Everolimus FDA Link 12/2017 - 12/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2017 - 01/2013
3	alpha-Fetoproteins (alpha-Fetoprotein)IBA 02/2016 - 10/2004
3	sipuleucel-T (APC8015)FDA Link 11/2015 - 05/2015
3	Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric 12/2014 - 08/2003
3	RANK LigandIBA 10/2013 - 07/2003
3	ZD4054IBA 05/2013 - 07/2012

Therapy/Procedure

171	Castration 07/2022 - 03/2002
113	Therapeutics 10/2022 - 03/2003
88	Drug Therapy (Chemotherapy) 06/2022 - 02/2002
21	Radiotherapy 01/2022 - 08/2003
7	Aftercare (After-Treatment) 01/2022 - 05/2009
6	Immunotherapy 01/2020 - 12/2006
4	Precision Medicine 06/2021 - 01/2014
4	Duration of Therapy 11/2020 - 10/2011